BioPharmSignal logoBioPharmSignal

Biotech News

Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer

Foghorn Therapeutics (FHTX)Foghorn TherapeuticsCompany update

WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Ryan Maynard will join the company as

Related news

FHTXFoghorn Therapeutics2026-08-06 11:00 EST

Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update

NRIXNurix Therapeutics2026-08-20 11:00 EST

Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer

ERASErasca2026-08-10 12:00 EST

Erasca Strengthens R&D Leadership with Appointment of Internationally Recognized Medical Oncologist Charles S. Fuchs, M.D., M.P.H., as President of R&D

BNTXBioNTech2026-08-03 09:00 EST

BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer

KYMRKymera2026-07-27 20:01 EST

Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer

GERNGeron2026-07-13 12:00 EST

Geron Announces Appointment of Chinmaya Rath as Chief Business Officer

ELVNEnliven Therapeutics2026-08-05 20:05 EST

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

KYMRKymera2026-07-28 20:01 EST

Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026

NRIXNurix Therapeutics2026-07-09 20:01 EST

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

View all latest news

Foghorn Therapeutics

Foghorn Therapeutics is an oncology company focused on chromatin biology and gene-regulation targets. Its platform seeks to create differentiated cancer therapies through epigenetic control.

Recent company news

FHTXFoghorn Therapeutics2026-08-06 11:00 EST

Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update

FHTXFoghorn Therapeutics2026-06-05 11:00 EST

Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026

FHTXFoghorn Therapeutics2026-05-12 11:00 EST

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May

FHTXFoghorn Therapeutics2026-05-07 11:00 EST

Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update

FHTXFoghorn Therapeutics2026-04-21 20:05 EST

Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

Stock data

Close
7.07 USD
Market cap
213.13M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States